Maris Medical Completes Tens of Millions RMB Series A Funding to Build an Integrated CRO Platform Spanning Medical Devices, Special Medical Foods, and Aesthetic Health

VCBeat has learned that, recently,Maris(Abbreviation: Maris)Announced Completion of Tens of Millions of YuanSeries A financing, with investors being Boqu Fund (managed by Qudao Assets) and WinX Capital Capital WinX Capital Serves as Exclusive Financial Advisor。Following the completion of this financing round, Maris will leverage its robustCRO Capabilities，Further Strengthening“Medical Devices + FSMP + Medical Aesthetics & Health” CRO Platform。

With over a decade of experience in medical device CRO services, the Maris team has established China’s largest CRO platform integrating “medical devices, foods for special medical purposes (FSMP), and medical aesthetics and health.” It is also one of the medical device CRO companies with the highest net profit margins in China. To further accelerate the registration and market launch of innovative medical devices and address the “last mile” challenges in industrialization for innovative medical device enterprises, Maris has extended its services from post-R&D stages to pre-market phases. Moreover, to break through the growth ceiling of traditional medical device CRO services, Maris has expanded its service scope from innovative medical devices to include regulatory consulting services in the two major fields of FSMP and medical aesthetics and health.

Wang Yang, founder of Maris, stated: We place great emphasis on service quality, which is one of Maris’s core service principles and the foundation of our business. We also sincerely appreciate the recognition from Qudao Asset Management and the comprehensive services provided by WinX Capital in equity structure design and capital planning. Founder Wang Yang believes that while the medical device CRO sector has many players, few manage to achieve significant scale and strength. Compared with the pharmaceutical sector, medical devices are far more diverse. Without profound industry experience and efficient learning capabilities, relying solely on a few products or orders in a single field would cause a company to be quickly overwhelmed by the rapid wave of innovative medical device development in China. Therefore, it is essential to continuously expand into adjacent areas, broaden service boundaries, and enhance corporate competitiveness. This development strategy has been summarized through extensive exploration, judgment, and practical experience. To date, Maris has served over 800 clients and assisted them in obtaining more than 1,500 registration certificates. In addition to its Beijing headquarters, Maris has established offices in Seoul (South Korea), Taipei, Shanghai, Shenyang, Shijiazhuang, and Xi’an, with stationed personnel in more than 17 provinces and municipalities across China.

Qudao Asset Management boasts extensive industrial resources and has joined forces with Maris to collaboratively drive development across the company’s three core sectors.“Medical Devices + FSMP + Medical Aesthetics and Health” are booming, and Maris is also experiencing rapid growth, thanks to its role as a “shovel seller.”For the booming medical device industry, Maris is committed to building comprehensive services across the entire industrial chain. In the rapidly growing aesthetic medicine and broader health sector, Maris will collaborate with upstream partners to provide enhanced service support, address production constraints, and accelerate industry advancement. Looking ahead to the burgeoning special medical food market, Maris leverages its extensive industry resources and the CRO platform to further drive development in this segment.

Zeng Haotian, Chairman and General Manager of Qudao Asset Management, stated: The foundation of a medical device CRO company’s development lies in “service quality,” a principle well exemplified by Maris. The company has previously remained silent in the capital markets, focusing instead on enhancing service quality and dedicating itself to creating value for clients. As a result, it has become one of the few enterprises in the medical device CRO sector that does not rely on a “heavy-asset narrative.” Furthermore, after conducting multiple industry research studies, engaging in mutual due diligence, and performing internal analyses, Qudao Capital recognizes the shared development strategy between Maris and the strategic investors in this funding round: leveraging its core medical device CRO business as the foundation, while expanding into specialized medical food and cosmetics CRO services as two complementary wings. This presents an opportune moment for accelerated growth. Throughout Maris’s future development, Qudao Capital and its managed healthcare funds will continue to provide steadfast support.

Guangzhou Qudao Asset Management Co., Ltd. (hereinafter referred to as “Qudao Asset”) is a professional private equity investment fund focused on the healthcare industry. Its investors include multiple publicly listed healthcare companies, government guidance funds, and overseas investors, such as Da An Gene, Hengji Daxin, Boji Medicine, and South China New Drug. The fund’s industrial resources extensively cover in vitro diagnostics, new drug R&D, CRO/CMO, and other sectors. The Qudao Asset team boasts extensive industry experience and a robust resource network, providing enterprises with strategic resources and capital market support through industry chain integration, strategic M&A, and equity investments.

WinX Capital is a leading investment bank in China’s healthcare sector. Five members of its founding team hold Ph.D.s in Global Finance from the PBC School of Finance at Tsinghua University, while its frontline team boasts an average of over 10 years of experience in management, investment, and mergers and acquisitions (M&A), with cumulative transaction values exceeding RMB 30 billion. Headquartered in Beijing and Shanghai, WinX Capital serves more than 3,000 active institutional investors and industrial groups. In 2020, it was ranked among the “Top 5 Most Promising New-Type Investment Banks in China” by 36Kr’s WISE 2020 list, and named one of the “Top 4 Best Financial Advisory Firms in Healthcare” for 2020 by Qiming Technology & Xinsheng Chuangfu.